當(dāng)前位置：首頁 SCI期刊 SCIE期刊醫(yī)學(xué) 中科院4區(qū) JCRQ2 期刊介紹(非官網(wǎng))

Hematological OncologySCIE

國際簡稱：HEMATOL ONCOL 參考譯名：血液腫瘤學(xué)

中科院分區(qū)
4區(qū)
CiteScore分區(qū)
Q2
JCR分區(qū)
Q2

基本信息：: ISSN：0278-0232; E-ISSN：1099-1069; 是否OA：未開放; 是否預(yù)警：否; TOP期刊：否

出版信息：: 出版地區(qū)：ENGLAND; 出版商：John Wiley and Sons Ltd; 出版語言：English; 出版周期：Quarterly; 出版年份：1983; 研究方向：血液學(xué)-醫(yī)學(xué)

評價信息：: 影響因子：3.3; H-index：42; CiteScore指數(shù)：4.2; SJR指數(shù)：0.82; SNIP指數(shù)：0.717

發(fā)文數(shù)據(jù)：: Gold OA文章占比：30.61%; 研究類文章占比：65.59%; 年發(fā)文量：93; 自引率：0.0606...; 開源占比：0.1672; 出版撤稿占比：0; 出版國人文章占比：0.09; OA被引用占比：0.1165...

投稿咨詢加急見刊

英文簡介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問題

英文簡介Hematological Oncology期刊介紹

Hematological Oncology considers for publication articles dealing with experimental and clinical aspects of neoplastic diseases of the hemopoietic and lymphoid systems and relevant related matters. Translational studies applying basic science to clinical issues are particularly welcomed. Manuscripts dealing with the following areas are encouraged:

-Clinical practice and management of hematological neoplasia, including: acute and chronic leukemias, malignant lymphomas, myeloproliferative disorders

-Diagnostic investigations, including imaging and laboratory assays

-Epidemiology, pathology and pathobiology of hematological neoplasia of hematological diseases

-Therapeutic issues including Phase 1, 2 or 3 trials as well as allogeneic and autologous stem cell transplantation studies

-Aspects of the cell biology, molecular biology, molecular genetics and cytogenetics of normal or diseased hematopoeisis and lymphopoiesis, including stem cells and cytokines and other regulatory systems.

Concise, topical review material is welcomed, especially if it makes new concepts and ideas accessible to a wider community. Proposals for review material may be discussed with the Editor-in-Chief. Collections of case material and case reports will be considered only if they have broader scientific or clinical relevance.

期刊簡介Hematological Oncology期刊介紹

《Hematological Oncology》自1983出版以來，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個領(lǐng)域的原創(chuàng)研究提供一個展示平臺，以促進醫(yī)學(xué)領(lǐng)域的的進步。該刊鼓勵先進的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見解，或?qū)彶槎嗄陙砟硞€重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時報道醫(yī)學(xué)領(lǐng)域的最新進展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫SCIE收錄，得到了廣泛的認可。

該期刊投稿重要關(guān)注點：

預(yù)計審稿時間： 12周，或約稿
醫(yī)學(xué)
HEMATOLOGY
SCIE
中科院4區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Hematological Oncology Cite Score數(shù)據(jù)

CiteScore：4.2
SJR：0.82
SNIP：0.717

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Hematology	Q2	65 / 137	52%
大類：Medicine 小類：Oncology	Q2	197 / 404	51%
大類：Medicine 小類：Cancer Research	Q3	146 / 230	36%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評價期刊影響力的文獻計量指標。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫中收集的引文為基礎(chǔ)，針對的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評價期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標來評價。

歷年Cite Score趨勢圖

中科院SCI分區(qū)Hematological Oncology 中科院分區(qū)

中科院 2023年12月升級版 綜述期刊：否 Top期刊：否

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	4區(qū)	HEMATOLOGY 血液學(xué) ONCOLOGY 腫瘤學(xué)	4區(qū) 4區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運用科學(xué)計量學(xué)方法對國際、國內(nèi)學(xué)術(shù)期刊依據(jù)影響力進行等級劃分的期刊評價標準。它為我國科研、教育機構(gòu)的管理人員、科研工作者提供了一份評價國際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國各地高校、科研機構(gòu)的廣泛認可。

中科院分區(qū)表 將所有期刊按照一定指標劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個層次，類似于“優(yōu)、良、及格”等。最開始，這個分區(qū)只是為了方便圖書管理及圖書情報領(lǐng)域的研究和期刊評估。之后中科院分區(qū)逐步發(fā)展成為了一種評價學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢圖

JCR分區(qū)Hematological Oncology JCR分區(qū)

2023-2024 年最新版

按JIF指標學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：HEMATOLOGY	SCIE	Q2	30 / 97	69.6%
學(xué)科：ONCOLOGY	SCIE	Q2	118 / 322	63.5%

按JCI指標學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：HEMATOLOGY	SCIE	Q3	49 / 97	50%
學(xué)科：ONCOLOGY	SCIE	Q3	212 / 322	34.32%

JCR分區(qū)的優(yōu)勢在于它可以幫助讀者對學(xué)術(shù)文獻質(zhì)量進行評估。不同學(xué)科的文章引用量可能存在較大的差異，此時單獨依靠影響因子(IF)評價期刊的質(zhì)量可能是存在一定問題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢圖

發(fā)文數(shù)據(jù)

2023-2024 年國家/地區(qū)發(fā)文量統(tǒng)計

國家/地區(qū)數(shù)量
Italy100
USA62
Japan48
CHINA MAINLAND45
Switzerland31
France26
GERMANY (FED REP GER)23
Israel17
Brazil13
England13

本刊中國學(xué)者近年發(fā)表論文

1、Clinical analysis of patients with primary and secondary extranodal natural killer/T-cell lymphoma of central nervous system
Author: Li, Xingying; Yu, Hui; Fu, Xiaorui; Zhang, Lei; Li, Xin; Li, Ling; Wang, Xinhua; Sun, Zhenchang; Zhang, Xudong; Li, Zhaoming; Wu, Jingjing; Chang, Yu; Yan, Jiaqin; Zhou, Zhiyuan; Nan, Feifei; Wu, Xiaolong; Tian, Li; Zhang, Mingzhi

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 267-274. DOI: 10.1002/hon.2894
2、Primary treatment and recent survival trends in patients with primary diffuse large B-cell lymphoma of central nervous system, 1995-2016: A population-based SEER analysis
Author: Chen, Cui; Sun, Peng; Sun, Xiao-Qing; Chen, Shao-Yong; Yang, Hang; Wang, Yu; Li, Zhi-Ming

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 248-256. DOI: 10.1002/hon.2918
3、Improved method to stratify lymphoma patients with risk of secondary central nervous system involvement: A multicenter retrospective analysis
Author: Lang, Mingxiao; Feng, Youqin; Meng, Xiangrui; Zhao, Jing; Song, Zheng; Qian, Zhengzi; Qiu, Lihua; Zhou, Shiyong; Liu, Xianming; Li, Lanfang; Yang, Haiyan; Song, Yuqin; Li, Wei; Zhang, Huilai

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 239-247. DOI: 10.1002/hon.2928
4、Review on natural killer/T-cell lymphoma
Author: He, Xiaohua; Gao, Yan; Li, Zhiming; Huang, Huiqiang

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 221-229. DOI: 10.1002/hon.2944
5、Synergistic anticancer effect of a combination of chidamide and etoposide against NK/T cell lymphoma
Author: Song, Wenting; Chen, Zhan; Shi, Cunzhen; Gao, Yuyang; Feng, Xiaoyan; Li, Hongwen; Li, Zhaoming; Zhang, Mingzhi

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 257-266. DOI: 10.1002/hon.2954
6、TAFRO syndrome with fatigue and abdominal distension as the first symptom: A case report
Author: Zhou, Bai; Tang, Chao; Chen, Guiyang; Jiang, Tiebin; Shi, Xiao; Wang, Fen

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 285-290. DOI: 10.1002/hon.2962
7、Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden
Author: Mu, Juan; Deng, Haobin; Lyu, Cuicui; Yuan, Jijun; Li, Qing; Wang, Jia; Jiang, Yanyu; Deng, Qi; Shen, Jichun

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 275-284. DOI: 10.1002/hon.2981
8、Elevated serum IL-13 level is associated with increased Treg cells in tumor microenvironment and disease progression of diffuse large B-cell lymphoma
Author: Li, Xiao; Liu, Mengke; Shi, Qing; Fang, Ying; Fu, Di; Shen, Zhi-xiang; Yi, Hongmei; Wang, Li; Zhao, Weili

Journal: HEMATOLOGICAL ONCOLOGY. 2023; Vol. 41, Issue 2, pp. 230-238. DOI: 10.1002/hon.2993